These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 11738740)

  • 21. Antigenic repertoire of Plasmodium vivax transmission-blocking vaccine candidates from the Indian subcontinent.
    Prajapati SK; Joshi H; Dua VK
    Malar J; 2011 May; 10():111. PubMed ID: 21535892
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic polymorphisms of Plasmodium vivax ookinete (sexual stage) surface proteins (Pvs25 and Pvs28) from Thailand.
    Kuesap J; Suphakhonchuwong N; Rungsihirunrat K
    Infect Genet Evol; 2024 Mar; 118():105558. PubMed ID: 38244749
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A rapid genotyping method for the vivax malaria transmission-blocking vaccine candidates, Pvs25 and Pvs28.
    Tsuboi T; Kaneko O; Cao YM; Tachibana M; Yoshihiro Y; Nagao T; Kanbara H; Torii M
    Parasitol Int; 2004 Sep; 53(3):211-6. PubMed ID: 15468527
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evolution of the Transmission-Blocking Vaccine Candidates Pvs28 and Pvs25 in Plasmodium vivax: Geographic Differentiation and Evidence of Positive Selection.
    Chaurio RA; Pacheco MA; Cornejo OE; Durrego E; Stanley CE; Castillo AI; Herrera S; Escalante AA
    PLoS Negl Trop Dis; 2016 Jun; 10(6):e0004786. PubMed ID: 27347876
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Limited sequence polymorphisms of four transmission-blocking vaccine candidate antigens in Plasmodium vivax Korean isolates.
    Kang JM; Ju HL; Moon SU; Cho PY; Bahk YY; Sohn WM; Park YK; Cha SH; Kim TS; Na BK
    Malar J; 2013 Apr; 12():144. PubMed ID: 23631662
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sequence polymorphisms of Plasmodium vivax ookinete surface proteins (Pvs25 and Pvs28) from clinical isolates in Korea.
    Han ET; Lee WJ; Sattabongkot J; Jang JW; Nam MH; An SS; Suh I; Lim CS
    Trop Med Int Health; 2010 Sep; 15(9):1072-6. PubMed ID: 20545923
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of Pvs28 in sporozoite development in Anopheles sinensis and its longevity in BALB/c mice.
    Kim TS; Kim HH; Moon SU; Lee SS; Shin EH; Oh CM; Kang YJ; Kim DK; Sohn Y; Kim H; Lee HW
    Exp Parasitol; 2011 Feb; 127(2):346-50. PubMed ID: 20801117
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasmodium vivax ookinete surface protein Pvs25 linked to cholera toxin B subunit induces potent transmission-blocking immunity by intranasal as well as subcutaneous immunization.
    Miyata T; Harakuni T; Tsuboi T; Sattabongkot J; Kohama H; Tachibana M; Matsuzaki G; Torii M; Arakawa T
    Infect Immun; 2010 Sep; 78(9):3773-82. PubMed ID: 20584978
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transmission blocking potency and immunogenicity of a plant-produced Pvs25-based subunit vaccine against Plasmodium vivax.
    Blagborough AM; Musiychuk K; Bi H; Jones RM; Chichester JA; Streatfield S; Sala KA; Zakutansky SE; Upton LM; Sinden RE; Brian I; Biswas S; Sattabonkot J; Yusibov V
    Vaccine; 2016 Jun; 34(28):3252-9. PubMed ID: 27177945
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tricomponent immunopotentiating system as a novel molecular design strategy for malaria vaccine development.
    Miyata T; Harakuni T; Tsuboi T; Sattabongkot J; Ikehara A; Tachibana M; Torii M; Matsuzaki G; Arakawa T
    Infect Immun; 2011 Oct; 79(10):4260-75. PubMed ID: 21807905
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The surface protein Pvs25 of Plasmodium vivax ookinetes interacts with calreticulin on the midgut apical surface of the malaria vector Anopheles albimanus.
    Rodríguez Mdel C; Martínez-Barnetche J; Alvarado-Delgado A; Batista C; Argotte-Ramos RS; Hernández-Martínez S; González Cerón L; Torres JA; Margos G; Rodríguez MH
    Mol Biochem Parasitol; 2007 Jun; 153(2):167-77. PubMed ID: 17442413
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Transmission-blocking vaccine candidate of Plasmodium vivax Pvs25 is highly conservative among Chinese isolates].
    Zheng L; Xu WM; Liu YJ; Yang YM; Cao YM
    Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2004 Feb; 22(1):16-9. PubMed ID: 15283259
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51.
    Wu Y; Ellis RD; Shaffer D; Fontes E; Malkin EM; Mahanty S; Fay MP; Narum D; Rausch K; Miles AP; Aebig J; Orcutt A; Muratova O; Song G; Lambert L; Zhu D; Miura K; Long C; Saul A; Miller LH; Durbin AP
    PLoS One; 2008 Jul; 3(7):e2636. PubMed ID: 18612426
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of Plasmodium vivax Cell-Traversal Protein for Ookinetes and Sporozoites as a Preerythrocytic P. vivax Vaccine.
    Alves E; Salman AM; Leoratti F; Lopez-Camacho C; Viveros-Sandoval ME; Lall A; El-Turabi A; Bachmann MF; Hill AV; Janse CJ; Khan SM; Reyes-Sandoval A
    Clin Vaccine Immunol; 2017 Apr; 24(4):. PubMed ID: 28179403
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A two-dose viral-vectored
    Yamamoto Y; Fabbri C; Okuhara D; Takagi R; Kawabata Y; Katayama T; Iyori M; Hasyim AA; Sakamoto A; Mizukami H; Shida H; Lopes S; Yoshida S
    Front Immunol; 2024; 15():1372584. PubMed ID: 38745665
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recombinant Pvs48/45 antigen expressed in E. coli generates antibodies that block malaria transmission in Anopheles albimanus mosquitoes.
    Arévalo-Herrera M; Vallejo AF; Rubiano K; Solarte Y; Marin C; Castellanos A; Céspedes N; Herrera S
    PLoS One; 2015; 10(3):e0119335. PubMed ID: 25775466
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Novel Ex Vivo Assay to Evaluate Functional Effectiveness of Plasmodium vivax Transmission-Blocking Vaccine Using Pvs25 Transgenic Plasmodium berghei.
    Cao Y; Hayashi CTH; Kumar N
    J Infect Dis; 2024 Jun; 229(6):1894-1903. PubMed ID: 38408353
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of transmission-blocking activity of candidate Pvs25 vaccine using gametocytes from chimpanzees.
    Collins WE; Barnwell JW; Sullivan JS; Nace D; Williams T; Bounngaseng A; Roberts J; Strobert E; McClure H; Saul A; Long CA
    Am J Trop Med Hyg; 2006 Feb; 74(2):215-21. PubMed ID: 16474073
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Highly efficient protein expression of Plasmodium vivax surface antigen, Pvs25, by silkworm and its biochemical analysis.
    Miyata T; Minamihata K; Kurihara K; Kamizuru Y; Gotanda M; Obayashi M; Kitagawa T; Sato K; Kimura M; Oyama K; Ikeda Y; Tamaki Y; Lee JM; Sakao K; Hamanaka D; Kusakabe T; Tachibana M; Ibrahim HR
    Protein Expr Purif; 2022 Aug; 195-196():106096. PubMed ID: 35460871
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of two Plasmodium vivax sexual stage antigens as transmission-blocking vaccine candidates.
    Zhang Y; Liu F; Zhao Y; Yang F; Bai J; Jia X; Roobsoong W; Sattabongkot J; Cui L; Cao Y; Luo E; Wang M
    Parasit Vectors; 2021 Aug; 14(1):407. PubMed ID: 34399829
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.